39 The Drug Rediscovery Protocol 17. Garcia, V.M., et al. Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research 20, 5663-5671 (2014). 18. Le, D.T., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New Engl J Med 372, 25092520 (2015). 19. Overman, M.J., et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18, 1182-1191 (2017). 20. van Waalwijk van Doorn-Khosrovani, S.B., et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol (2019). 21. Priestley P, B.J., Lolkema M, et al. Pan-cancer whole genome analyses of metastatic solid tumors. bioRxiv (2018). 22. Griffith, M., et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet 49, 170-174 (2017). 23. Chakravarty, D., et al. OncoKB: A Precision Oncology Knowledge Base. Jco Precis Oncol 1(2017). 24. Tamborero, D., et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med 10(2018). 25. Mateo, J., et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29, 1895-1902 (2018). 26. Sleijfer, S. & Wagner, A.J. The Challenge of Choosing Appropriate End Points in Single-Arm Phase II Studies of Rare Diseases. Journal of Clinical Oncology 30, 896-898 (2012). 27. T, R. CMS-Proposed Coverage of NGS Cancer Tests Could Lead to Off-Label Scripts, Oncologists Worry, 360Dx. (NEW YORK, GenomeWeb, 2018). 28. Meric-Bernstam, F., et al. A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Jnci-J Natl Cancer I 107(2015). 29. Cheson, B.D., et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology 32, 3059-+ (2014). 30. Rajkumar, S.V., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15, E538-E548 (2014). 31. Rustin, G.J.S., et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21, 419-423 (2011). 32. Therasse, P., et al. New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer I 92, 205-216 (2000). 2
RkJQdWJsaXNoZXIy MTk4NDMw